In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received ...

Editor's note: This story has been revised to include additional comments. CHICAGO — In patients with stage IVB anaplastic ...

Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Cue Biopharma (CUE – Research Report), with a ...

BT-001 replicated in the tumor and expressed the encoded GM-CSF and anti-CTLA-4 transgenes. Notably, BT-001 in combination with pembrolizumab showed first signs of efficacy in 2 out of 6 patients, ...

Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy, followed by adjuvant pembrolizumab demonstrated significant overall-survival improvement in patients with ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...